

# Technical Data Sheet

## InVivoMAb anti-human PD-L1 (B7-H1)



**Attention:** Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

### Lot Specific Information

**Lot Number:** Lot Specific\*  
**Volume:** Lot Specific\*  
**Concentration:** Lot Specific\* (generally 4 to 11 mg/ml) \*  
**Total Protein:** Lot Specific\*

\*This information will be noted on the certificate of analysis that ships with this product.

### Product Information

**Catalog Number:** BE0285  
**Clone:** 29E.2A3  
**Isotype:** Mouse IgG2b,  $\kappa$   
**Recommended Isotype Control(s):** InVivoMAb mouse IgG2b isotype control, unknown specificity  
**Recommended Dilution Buffer:** InVivoPure pH 7.0 Dilution Buffer  
**Immunogen:** Full length human PD-L1  
**Reported Applications:** *in vitro* PD-L1 blockade  
Functional assays  
Immunohistochemistry (frozen)  
Flow cytometry  
**Formulation:** PBS, pH 7.0  
Contains no stabilizers or preservatives  
**Endotoxin:** <2EU/mg (<0.002EU/ $\mu$ g)  
Determined by LAL gel clotting assay  
**Purity:** >95%  
Determined by SDS-PAGE  
**Sterility:** 0.2  $\mu$ m filtration  
**Production:** Purified from cell culture supernatant in an animal-free facility  
**Purification:** Protein G  
**RRID:** [AB\\_2687808](https://eutils.ncbi.nlm.nih.gov/entrez/eutils/rrid.cgi?db=AB)  
**Molecular Weight:** 150 kDa

### Description

The 29E.2A3 monoclonal antibody reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed on T lymphocytes, B lymphocytes, NK cells, dendritic cells, as well as IFN $\gamma$  stimulated monocytes, epithelial cells and endothelial cells. PD-L1 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L1 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. PD-L1 is thought to play an important role in tumor immune evasion. Induced PD-L1 expression is common in many tumors and results in increased resistance of tumor cells to CD8 T cell mediated lysis. The 29E.2A3 antibody has been shown to block the binding of PD-1-Ig to PD-L1.

### Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

## Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.


## Application References

For a complete list of references, visit [https://bioxcell.com/be0285?bxcs=9k1b3a#tab\\_references](https://bioxcell.com/be0285?bxcs=9k1b3a#tab_references) or scan the QR code below.



## Binding Validation

Validation data shown below confirms that this clone binds to its target antigen. For lot specific binding validation data, e-mail [technicalservice@bioxcell.com](mailto:technicalservice@bioxcell.com).



**Bio X Cell, LLC**  
<https://bioxcell.com>  
+1-866-787-3444  
[customerservice@bioxcell.com](mailto:customerservice@bioxcell.com)

*Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.*

*Not for resale.*

**Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC**